tert-butyl (2S,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}-2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]pyrrolidine-1-carboxylate | 137955-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl (2S,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}-2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]pyrrolidine-1-carboxylate
• 英文别名: (2S,4R)-N-t-butoxycarbonyl-4-t-butyldimethylsilyloxy-2-[(E)-2-ethoxycarbonylvinyl]pyrrolidine；tert-butyl (2S,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}-2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl] pyrrolidine-1-carboxylate；Ethyl 3-[(2S,4R)-4-tert-butyldimethylsiloxy-N-tert-butoxycarbonylpyrrolidin-2-yl]acrylate；tert-butyl (2S,4R)-4-[tert-butyl(dimethyl)silyl]oxy-2-[(E)-3-ethoxy-3-oxoprop-1-enyl]pyrrolidine-1-carboxylate
• CAS: 137955-35-2
• 化学式: C₂₀H₃₇NO₅Si
• 分子量: 399.603
• InChiKey: QVOBTVSKXXGUCZ-NFGWICIOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.51
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl (2S,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}-2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]pyrrolidine-1-carboxylate 在 镍 盐酸 、 sodium hydroxide 、 氢气 、 sodium hydride 、 N,N-二异丙基乙胺 、 三苯基膦 、 偶氮二甲酸二乙酯 、 四甲基胍 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 乙腈 为溶剂， 反应 0.25h， 生成 (4-nitrophenyl)methyl (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-3-[(3S,5S)-5-[(3S)-1-methylpyrrolidin-3-yl]-1-[(4-nitrophenyl)methoxycarbonyl]pyrrolidin-3-yl]sulfanyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
  参考文献：
  名称：

  1个β-甲基-2（5-取代的吡咯烷-3-基硫基）卡巴南。1. BO-2502A及其相关化合物的合成和抗菌活性。

  摘要：

  （1R，5S，6S）-2-[（3S，5S）-5-取代的吡咯烷-3-基硫基] -6-[[（R）-1-羟乙基] -1-甲基-1）的合成和生物活性描述了其中引入内酰胺和环状胺作为取代基的-ca rbapen-2-em-3-羧酸。他们显示出对革兰氏阳性和革兰氏阴性细菌（包括铜绿假单胞菌）的有效抗菌活性。其中，选择了BO-2502A（4h-1）进行进一步评估。

  DOI：

  10.7164/antibiotics.50.567
• 作为产物：
  描述：

  1-tert-butyl 2-methyl (2S,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}pyrrolidine-1,2-dicarboxylate 在 lithium aluminium tetrahydride 、 sodium hydride 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 二氯甲烷 、 mineral oil 为溶剂， 反应 3.5h， 生成 tert-butyl (2S,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}-2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]pyrrolidine-1-carboxylate
  参考文献：
  名称：

  [EN] BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS
  [FR] COMPOSÉS AZA BICYCLIQUES EN TANT QU'AGONISTES DU RÉCEPTEUR MUSCARINIQUE M1.

  摘要：

  公开号：

  WO2015118342A8

文献信息

• 1.BETA.-Methyl-2-(5-substituted pyrrolidin-3-ylthio)carbapenems; 2. Synthesis and Antibacterial Activity of 5-Aminopropyl and 5-Aminopropenyl Pyrrolidine Derivatives.
  作者：NORIKAZU OHTAKE、OSAMU OKAMOTO、SHINJI KATO、RYOSUKE USHIJIMA、HIROSHI FUKATSU、SUSUMU NAKAGAWA

  DOI：10.7164/antibiotics.50.586

  日期：——

  The synthesis and biological activity of (1 R, 5S, 6S)-2-[(3S, 5S)-5-substituted pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methyl-1- carbapen-2-em-3-carboxylic acid, in which aminopropyl, aminopropenyl, and aminopropynyl groups were introduced as substituents, are described. Aminopropyl and aminopropenyl derivatives showed potent in vitro and in vivo antibacterial activity against Gram-positive

  （1 R，5S，6S）-2-[（3S，5S）-5-取代的吡咯烷-3-基硫基] -6-[[（R）-1-羟乙基] -1-甲基-描述了其中引入了氨基丙基，氨基丙烯基和氨基丙炔基作为取代基的1-碳青烯-2-em-3-羧酸。氨丙基和氨基丙烯基衍生物对革兰氏阳性和革兰氏阴性细菌（包括铜绿假单胞菌）显示出有效的体外和体内抗菌活性。
• 2-(substituted pyrrolidinylthio)carbapenem derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05374720A1

  公开（公告）日：1994-12-20

  A compound of the formula: ##STR1## wherein R is a hydrogen atom or a methyl group, R.sup.1 is a hydrogen atom or a negative charge, each of R.sup.2 and R.sup.3 which may be the same or different, is a hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group, a formimidoyl group, an acetoimidoyl group, --COOR.sup.4, --CON(R.sup.5)R.sup.6, --N(R.sup.5)R.sup.6, --CH.sub.2 COOR.sup.4, --CH.sub.2 N(R.sup.5)R.sup.6 or --CH.sub.2 CON(R.sup.5)R.sup.6 (wherein R.sup.4 is a hydrogen atom or a lower alkyl group, each of R.sup.5 and R.sup.6 which may be the same or different, is a hydrogen atom or a lower alkyl group, or R.sup.5 and R.sup.6 form together with the adjacent nitrogen atom a heterocyclic group selected from the group consisting of an aziridinyl group, an azetidinyl group, a pyrrolidinyl group and a piperidyl group), A is .dbd.NR.sup.7, .dbd.N.sup.+ (R.sup.7)R.sup.8, wherein each of R.sup.7 and R.sup.8 which may be the same or different, is a hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group, a formimidoyl group, an acetoimidoyl group, --COOR.sup.4, --CON(R.sup.5)R.sup.6, --N(R.sup.5)R.sup.6, --CH.sub.2 COOR.sup.4, --CH.sub.2 N(R.sup.5)R.sup.6 or --CH.sub.2 CON(R.sup.5)R.sup.6 (wherein R.sup.4, R.sup.5 and R.sup.6 are as defined above), p is an integer of from 0 to 3, and q is an integer of from 1 to 3; or a pharmaceutically acceptable salt or ester thereof.

  该化合物的公式为：##STR1##，其中R是氢原子或甲基基团，R.sup.1是氢原子或负电荷，R.sup.2和R.sup.3可以是相同的或不同的，是氢原子、低级烷基团、羟基低级烷基团、甲酰亚胺基团、乙酰亚胺基团、--COOR.sup.4、--CON(R.sup.5)R.sup.6、--N(R.sup.5)R.sup.6、--CH.sub.2 COOR.sup.4、--CH.sub.2 N(R.sup.5)R.sup.6或--CH.sub.2 CON(R.sup.5)R.sup.6（其中R.sup.4是氢原子或低级烷基团，R.sup.5和R.sup.6可以是相同的或不同的，是氢原子或低级烷基团，或者R.sup.5和R.sup.6与相邻的氮原子共同形成一个杂环组，选自包括氮环丙烷基团、氮环丁烷基团、吡咯烷基团和哌啶基团在内的组中），A是.dbd.NR.sup.7，.dbd.N.sup.+ (R.sup.7)R.sup.8，其中R.sup.7和R.sup.8可以是相同的或不同的，是氢原子、低级烷基团、羟基低级烷基团、甲酰亚胺基团、乙酰亚胺基团、--COOR.sup.4、--CON(R.sup.5)R.sup.6、--N(R.sup.5)R.sup.6、--CH.sub.2 COOR.sup.4、--CH.sub.2 N(R.sup.5)R.sup.6或--CH.sub.2 CON(R.sup.5)R.sup.6（其中R.sup.4、R.sup.5和R.sup.6如上所述定义），p是从0到3的整数，q是从1到3的整数；或其药用可接受的盐或酯。
• 1,a-Methyl-2-(5-substituted pyrrolidin-3-ylthio)carbapenems; 3. Synthesis and Antibacterial Activity of BO-2727 and Its Related Compounds.
  作者：NORIKAZU OHTAKE、OSAMU OKAMOTO、RYUJI MITOMO、YOSHIAKI KATO、KATSUMI YAMAMOTO、YUJI HAGA、HIROSHI FUKATSU、SUSUMU NAKAGAWA

  DOI：10.7164/antibiotics.50.598

  日期：——

  The synthesis and biological activity of (1R,5S,6S)-2-[(3S,5S)- 5-substituted pyrrolidin-3-ylthio]- 6-[(R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid in which hydroxy-substituted aminoethyl, aminopropyl, and aminobutyl groups were introduced as substituents, are described. These derivatives showed potent antibacterial activity against Gram-positive and Gram-negative bacteria including

  （1R，5S，6S）-2-[（3S，5S）-5取代的吡咯烷-3-基硫基] -6-[（（R）-1-羟乙基] -1-甲基-1）的合成和生物活性描述了其中引入了羟基取代的氨基乙基，氨基丙基和氨基丁基作为取代基的-咔啉-2-em-3-羧酸。这些衍生物对包括铜绿假单胞菌在内的革兰氏阳性和革兰氏阴性细菌显示出有效的抗菌活性。其中，选择带有（R）-1-羟基-3-（N-甲基氨基）丙基的来那培南（BO-2727，7b）作为开发候选。
• Aminoalkylpyrrolidinylthiocarbapenem derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05550121A1

  公开（公告）日：1996-08-27

  A compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or a methyl group, R.sup.2 is a hydrogen atom or a negative charge, R.sup.3 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkoxy group, a lower alkanoyloxy group, an amino group, an N-lower alkylamino group, an N,N-di-lower alkylamino group, a lower alkanoylamino group, an aroylamino group, a (lower alkylsulfonyl)amino group, a sulfamoylamino group, a cyano group, a nitro group, a group of --COOR.sup.4 (wherein R.sup.4 is a hydrogen atom or a lower alkyl group) or a group of --CON(R.sup.5)R.sup.6 (wherein each of R.sup.5 and R.sup.6 which may be the same or different, is a hydrogen atom or a lower alkyl group, or R.sup.5 and R.sup.6 form together with the adjacent nitrogen atom a heterocyclic group selected from the group consisting of an aziridinyl group, an azetidinyl group, a pyrrolidinyl group, a piperidyl group, a piperazinyl group, a 4-lower alkyl piperazinyl group and a morpholino group), A is a linear or branched lower alkylene group, X is a group of --N(R.sup.7)R.sup.8 (wherein each of R.sup.7 and R.sup.8 which may be the same or different, is a hydrogen atom or a lower alkyl group) or a group of --N.sup.+ (R.sup.9)(R.sup.10)R.sup.11 (wherein each of R.sup.9, R.sup.10 and R.sup.11 which may be the same or different, is a lower alkyl group), provided that when A is a linear lower alkylene group, R.sup.3 is other than a hydrogen atom; or a pharmaceutically acceptable salt or ester thereof.

  该化合物的式子为：##STR1## 其中R.sup.1是氢原子或甲基基团，R.sup.2是氢原子或负电荷，R.sup.3是氢原子、卤素原子、羟基、较低的烷氧基、较低的烷酰氧基、氨基、N-较低烷基氨基、N,N-二较低烷基氨基、较低烷酰氨基、芳酰氨基、(较低烷基磺酰)氨基、磺酰胺氨基、氰基、硝基、--COOR.sup.4（其中R.sup.4是氢原子或较低烷基）或--CON（R.sup.5）R.sup.6（其中R.sup.5和R.sup.6可以相同或不同，是氢原子或较低烷基，或R.sup.5和R.sup.6与相邻的氮原子一起形成从以下组成的杂环基团中选择的杂环基团：氮杂环羟胺基、氮杂环四元环基团、吡咯烷基团、哌啶基团、哌嗪基团、4-较低烷基哌嗪基团和吗啉基团），A是线性或支链状的较低烷基烷基链，X是--N（R.sup.7）R.sup.8（其中每个R.sup.7和R.sup.8可以相同或不同，是氢原子或较低烷基）或--N.sup.+（R.sup.9）（R.sup.10）R.sup.11（其中每个R.sup.9，R.sup.10和R.sup.11可以相同或不同，是较低烷基），但当A是线性较低烷基烷基链时，R.sup.3不是氢原子；或其药学上可接受的盐或酯。
• 2-(substituted pyrrolidinylthio) carbapenem derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05373002A1

  公开（公告）日：1994-12-13

  A compound of the formula: ##STR1## wherein R is a hydrogen atom or a methyl group, R.sup.1 is a hydrogen atom or a negative charge, R.sup.2 is a lower alkyl group, a lower alkyl group substituted with a hydroxyl group or --COOR.sup.3 (wherein R.sup.3 is a hydrogen atom or a lower alkyl group), A is .dbd.NH, .dbd.NR.sup.4 or .dbd.N(R.sup.4)R.sup.5 (wherein each of R.sup.4 and R.sup.5 which may be the same or different, is a lower alkyl group or a lower alkyl group substituted with a hydroxyl group), p is an integer of from 0 to 3, and each of q and r which may be the same or different, is an integer of from 0 to 5, provided that q and r are not simultaneously 0 and q +r.ltoreq.6; or a pharmaceutically acceptable salt or ester thereof.

  一种化合物的公式：##STR1## 其中R是氢原子或甲基基团，R.sup.1是氢原子或负电荷，R.sup.2是较低的烷基基团，带有羟基取代的较低的烷基基团或--COOR.sup.3（其中R.sup.3是氢原子或较低的烷基基团），A是.dbd.NH，.dbd.NR.sup.4或.dbd.N（R.sup.4）R.sup.5（其中每个R.sup.4和R.sup.5可能相同或不同，是较低的烷基基团或带有羟基的较低的烷基基团），p是从0到3的整数，每个q和r可能相同或不同，是从0到5的整数，但q和r不能同时为0且q +r.ltoreq.6; 或其药学上可接受的盐或酯。